

Rev03
Update: Dec,14,2021

DATASHEET

TRAIL R-2, Human

Cat. No.: Z03095

Product Introduction

Species	Human
Protein Construction	TRAIL R-2 (Ala54-Glu182) Accession # Q6FH58
Purity	> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC
Endotoxin Level	< 0.2 EU/μg of protein by gel clotting method
Biological Activity	ED ₅₀ < 6.0 ng/ml, measured in a cell proliferation assay using RPMI-8226 cells in the presence of 25.0 ng/ml of human TRAIL.
Expression System	HEK 293
Apparent Molecular Weight	~15 kDa, on SDS-PAGE under reducing conditions.
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Background

Target Background : TRAIL Receptor-2 is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 is associated with a decrease in the survival rates of breast cancer patients.

Synonyms : TNFRSF10B; CD262; DR5; KILLER; KILLER/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9; tumor necrosis factor receptor superfamily member 10b; TNF receptor superfamily member 10b

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.